1. ADVERSE EVENTS OF THE COVID VACCINE IN TERTIARY CARE CENTRE IN BUNDELKHAND REGION: AN OBSERVATIONAL STUDY
- Author
-
Vimal Arya, Vinay Kumar, Sadhna Kauhsik, and Narendra Singh Sengar
- Abstract
The Drugs Controller General (India) approved COVAXIN and COVISHIELD. Ever since the corona vaccine was launched in India, it has been playing the important role in controlling the pandemic. As with all medicinal products, vaccine safety must continue to be monitored and it is not possible to identify and record many adverse events in a shorter duration, protected environment and restricted population in trials. During the mass vaccination, a total of 1377 recipients were recognised with adverse events. Total 54.39% male and 45.61% female recipients were experienced adverse events. In the 18-45 age group total of 83.01% people while in the >45 age group 16.99% people were vaccinated. A total of 3032 Non-serious adverse events were reported in 1377 persons in study duration. The most common adverse event reported was fatigue, followed by headache. Another common adverse event was injection site pain and fever in the population. Another side less common adverse events were muscle ache followed by pruritus. Most of the adverse events were experienced by the Covishield vaccine. However, all the adverse events were recovered within a week. Our study showed that all the adverse events were non-serious in nature and no one needed hospitalisation for adverse events
- Published
- 2022